419 results on '"Hayakawa, Fumihiko"'
Search Results
2. JSH practical guidelines for hematological malignancies, 2023: leukemia-3. Acute lymphoblastic leukemia/lymphoblastic lymphoma: ALL/LBL
3. Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia
4. EBF1–JAK2 inhibits the PAX5 function through physical interaction with PAX5 and kinase activity
5. VWF‐Gly2752Ser, a novel non‐cysteine substitution variant in the CK domain, exhibits severe secretory impairment by hampering C‐terminal dimer formation
6. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations
7. Dasatinib-based 2-step induction for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
8. Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy
9. Essential role of a carboxyl‐terminal α‐helix motif in the secretion of coagulation factor XI
10. Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma
11. RGS1 and CREB5 are direct and common transcriptional targets of ZNF384‐fusion proteins.
12. NUP98‐BPTF promotes oncogenic transformation through PIM1 upregulation.
13. Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL cells
14. Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient
15. JSH practical guidelines for hematological malignancies, 2018: I. leukemia—3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL)
16. Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor
17. NUP98-BPTF promotes oncogenic transformation through PIM1 upregulation
18. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases
19. Biology and management of primary effusion lymphoma
20. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations
21. Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity
22. Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission
23. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL
24. Data from Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia
25. Supplementary Data from Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia
26. VWF‐Gly2752Ser, a novel non‐cysteine substitution variant in the CK domain, exhibits severe secretory impairment by hampering C‐terminal dimer formation
27. A case of pemphigus with anti-desmoglein 3 and anti-desmocollin 2 and 3 autoantibodies, associated with follicular lymphoma and bronchiolitis obliterans
28. Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia
29. Functional inhibition of MEF2 by C/EBP is a possible mechanism of leukemia development by CEBP‐IGH fusion gene
30. Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study
31. Oncogenic lesions and molecular subtypes in adults with B‐cell acute lymphoblastic leukemia
32. BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia
33. F9 mRNA splicing aberration due to a deep Intronic structural variation in a patient with moderate hemophilia B
34. Periosteum-derived podoplanin-expressing stromal cells regulate nascent vascularization during epiphyseal marrow development
35. Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases
36. Protein S-Leu17Pro disrupts the hydrophobicity of its signal peptide causing a proteasome-dependent degradation
37. Functional inhibition of MEF2 by C/EBP is a possible mechanism of leukemia development by CEBP‐IGH fusion gene.
38. Oncogenic lesions and molecular subtypes in adults with B‐cell acute lymphoblastic leukemia.
39. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
40. Periosteum-derived podoplanin-expressing stromal cells regulate nascent vascularization during epiphyseal marrow development
41. Suppression of Super-Enhancer-Driven TAL1 Expression By KLF4 in T-Cell Acute Lymphoblastic Leukemia
42. Suppression of super-enhancer-driven TAL1expression by KLF4 in T-cell acute lymphoblastic leukemia
43. Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy
44. Establishment of a Stroma-Dependent Human Acute Myelomonocytic Leukemia Cell Line, NAMO-2, with FLT3 Tandem Duplication
45. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
46. c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300
47. Aberrant X chromosomal rearrangement through multi‐step template switching during sister chromatid formation in a patient with severe hemophilia A
48. High prevalence of MEF2D fusion in human B‐cell precursor acute lymphoblastic leukemia cell lines
49. Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia
50. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.